(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
27 December 2007 (27.12.2007)

PCT

(10) International Publication Number
WO 2007/149728 A2

(51) International Patent Classification: Not classified

(21) International Application Number:
PCT/US2007/070931

(22) International Filing Date: 12 June 2007 (12.06.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/814,971 20 June 2006 (20.06.2006) US

(71) Applicant: **ALCON MANUFACTURING, LTD.** [US/US]; 6201 South Freeway, Fort Worth, TX 76134-2099 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **MOHAPATRA, Suchismita** [IN/US]; 6405 Creekbend Court, Arlington, TX 76001 (US). **HELLBERG, Mark, R.** [US/US]; 3002 Oak Cove Road, Arlington, TX 76017 (US). **FENG, Zixia** [US/US]; 4204 Hideaway Drive, Arlington, TX 76017 (US).

(74) Agents: **RYAN, Patrick, M.** et al.; Alcon Research, Ltd., IP Legal TB4-8, 6201 South Freeway, Fort Worth, TX 76134-2099 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:
— *of inventorship (Rule 4.17(iv))*

Published:
— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2007/149728 A2

(54) Title: ARYL AND HETEROARYL TETRAHYDROBENZAZEPINE DERIVATIVES AND THEIR USE FOR TREATING GLAUCOMA

(57) Abstract: Aryl tetrahydrobenzazepine derivatives with minimal 5-HT_{2B} activity relative to 5-HT_{2A} and 5-HT_{2C} activity that are useful for treating glaucoma are disclosed.

ARYL AND HETEROARYL TETRAHYDROBENZAZEPINE DERIVATIVES AND THEIR USE FOR TREATING GLAUCOMA

The present invention is directed to compounds useful for treating ophthalmic diseases. In particular, the present invention is directed toward aryl and heteroaryl tetrahydrobenzazepine derivatives and their use for lowering and controlling intraocular pressure (IOP) and treating glaucoma.

Background of the Invention

The disease state referred to as glaucoma is characterized by a permanent loss of visual function due to irreversible damage to the optic nerve. The several morphologically or functionally distinct types of glaucoma are typically characterized by elevated IOP, which is considered to be causally related to the pathological course of the disease. Ocular hypertension is a condition wherein intraocular pressure is elevated, but no apparent loss of visual function has occurred; such patients are considered to be a high risk for the eventual development of the visual loss associated with glaucoma. Some patients with glaucomatous field loss have relatively low intraocular pressure. These so called normotension or low tension glaucoma patients can also benefit from agents that lower and control IOP. If glaucoma or ocular hypertension is detected early and treated promptly with medications that effectively reduce elevated intraocular pressure, loss of visual function or its progressive deterioration can generally be ameliorated. Drug therapies that have proven to be effective for the reduction of intraocular pressure include both agents that decrease aqueous humor production and agents that increase the outflow facility. Such therapies are in general administered by one of two possible routes, topically (direct application to the eye) or orally.

There are some individuals who do not respond well when treated with certain existing glaucoma therapies. There is, therefore, a need for other topical therapeutic agents that control IOP.

It has been found that serotonergic compounds which possess agonist activity at 5-HT_2 receptors effectively lower and control normal and elevated IOP and are useful for treating glaucoma, see U.S. Patent No. 6,664,286.

Compounds that act as agonists at 5-HT_2 receptors are well known and have shown a variety of utilities, primarily for disorders or conditions associated with the central nervous system (CNS). U.S. Patent 5,494,928 discloses certain 2-(indol-1-yl)-ethylamine analogs that are 5-HT_{2C} agonists for the treatment of obsessive compulsive disorder and other CNS derived personality disorders. U.S. Patent 5,571,833 discloses tryptamine analogs that are 5-HT_2 agonists for the treatment of portal hypertension and migraine. U.S. Patent 5,874,477 discloses a method for treating malaria using 5-$HT_{2A/2C}$ agonists. U.S. Patent 5,902,815 discloses the use of 5-HT_{2A} agonists to prevent adverse effects of NMDA receptor hypo-function. WO98/31354A2 discloses 5-HT_{2B} agonists for the treatment of depression and other CNS conditions. Agonist response at the 5-HT_{2A} receptor is reported to be the primary activity responsible for hallucinogenic activity, with some lesser involvement of the 5-HT_{2C} receptor possible [Psychopharmacology, Vol. 121:357, 1995].

WO 2005042491 discloses the following compounds as selective 5-HT_{2c} agonists useful for the treatment of obesity and related disorders:



A



B

Additionally, WO 2002074746 and WO 199300094 disclose series of nor-methyl tetrahydrobenzazepine analogs useful in the treatment of disorders characterized by excessive vasodilation. None of these references describes the use of the substituted aryl tetrahydrobenzazepines of the present invention for treating glaucoma.

Summary of the Invention

The present invention is directed toward certain aryl and heteroaryl tetrahydrobenzazepine derivatives that can be used to lower and control IOP and treat glaucoma in warm blooded animals, including man. The compounds are preferably formulated in pharmaceutical compositions suitable for topical delivery to the eye.

Among other factors, the present invention is based on the finding that compounds that function as 5-$HT_{2A/2C}$ agonists with low or no 5-HT_{2B} agonist potency (reported to be responsible for cardiovascular side effects) can be designed.

Description of the Preferred Embodiments

Compounds that are useful for lowering and controlling normal or elevated IOP and treating glaucoma according to the present invention are represented by the following formula:



Formula **A**

wherein

R^1 = H or C_{1-4} alkyl;

R^2 = H, OH, or OR where R = C_{1-4} alkyl;

R^3 = -X-Ar, $-OR^8$, $-(CH_2)_nOR^8$, or $-(CH_2)_{n'}-O-(CH_2)_mOR^8$;

R^4, R^5 = H or C_{1-2} alkyl;

R^6, R^7 = H or C_{1-2} alkyl;

when R^4 or R^5 = C_{1-2} alkyl , then R^6 = R^7 = H;

when R^6 or R^7 = C_{1-2} alkyl, then R^4 = R^5 = H;

R^8, R^9, R^{10} = H or C_{1-4} alkyl;

n = 1-4;

n' = 1-4;

m = 1-4;

X = O, $-C(R^9)(R^{10})-$, $-OC(R^9)(R^{10})-$, or $-C(R^9)(R^{10})O-$;

Ar = phenyl, optionally mono- or di-substituted with F, Cl, Br, I, C_{1-4} alkyl, OH, or OR^8; or 2-, 3-, 4- pyridyl, optionally mono- or di-substituted with F, Cl, Br, I, C_{1-4} alkyl, OH, or OR^8;
and pharmaceutically acceptable salts thereof.

Novel compounds of formula **A** are those wherein:

R^1 = H;
R^2 = H, OH, or OR where R = C_{1-4} alkyl;
R^3 = -X-Ar, $-OR^8$, $-(CH_2)_nOR^8$, or $-(CH_2)_{n'}-O-(CH_2)_mOR^8$;
R^4, R^5 = H;
R^6, R^7 = H;
R^8 = C_{1-4} alkyl;
R^9, R^{10} = H or C_{1-4} alkyl;
n = 1-4;
n' = 1-4;
m = 2-4;
X = O, $-C(R^9)(R^{10})-$, $-OC(R^9)(R^{10})-$, or $-C(R^9)(R^{10})O-$;
Ar = phenyl, optionally mono- or di-substituted with F, Cl, Br, C_{1-2} alkyl, OH, or OR^8; or 2-, 3-, 4- pyridyl, optionally mono- or di-substituted with F, Cl, Br, I, C_{1-4} alkyl, OH, or OR^8;
and pharmaceutically acceptable salts thereof.

Pharmaceutically acceptable addition salts include pharmaceutically acceptable acid addition salts prepared from acids including but not limited to acetic acid, benzenesulfonic acid, citric acid, fumaric acid, hydrobomic acid, hydrochloric acid, maleic acid, tartaric acid, phosphoric acid, sulfuric acid and the like. The acid addition salts may be obtained as the direct product of compound synthesis. Alternatively, the free base may be dissolved in a suitable solvent containing the appropriate acid, and the salt isolated by evaporation of the solvent or otherwise separating the salt and solvent. The compound of this invention may form solvates with standard low molecular weight solvents using methods know to those skilled in the art.

It is recognized that compounds of Formula **A** can contain one or more chiral centers. This invention contemplates all enantiomers, diastereomers, and mixtures thereof.

In the above definitions, the total number of carbon atoms in a substituent group is indicated by the C_{i-j} prefix where the numbers i and j define the number of carbon atoms; this definition includes straight chain, branched chain, and cyclic alkyl or (cyclic alkyl)alkyl groups.

Preferred compounds of Formula **A** are those in which:

R_1 = H;

R_2 = OH, or OR, where R = C_{1-4} alkyl;

R_3 = -X-Ar, $-OR^8$, $-(CH_2)_nOR^8$, or $-(CH_2)_n-O-(CH_2)_mOR^8$;

R^4, R^5 = H or C_1 alkyl;

R^6, R^7 = H or C_1 alkyl;

when R^4 or R^5 = C_1 alkyl, then R^6 = R^7 = H;

when R^6 or R^7 = C_1 alkyl, then R^4 = R^5 = H;

R^8 = C_{1-4} alkyl;

R^9, R^{10} = H or C_{1-4} alkyl; and

Ar = phenyl, optionally mono- or di-substituted with F, Cl, Br, C_{1-2} alkyl, OH, or OR^8.

The most preferred compounds are: 7-(3-Methoxy-benzyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine fumarate (Compound 1) and 8-(4-Hydroxy-benzyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ol hydrobromide (Compound 5), both of which are novel.

Preferred novel compounds of Formula **A** are those in which R = C_1 alkyl.

SYNTHESIS

The compounds of this invention can be prepared by known methods including those reported in WO 93/00094, WO 2005/042490, WO 2005/042491, and WO 2006/018260. The invention will be described in greater detail by way of specific examples. The following examples are offered for illustrative purposes only and are not intended to limit the invention in any manner

Scheme 1



Scheme 2



Scheme 3



Scheme 4



Example 1

7-(3-Methoxy-benzyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (1)

7-(3-Methoxy-benzyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (1) was prepared by the multiple step process outlined below.

Preparation of 2-Chloro-N-[2-(4-chloro-phenyl)-ethyl]-acetamide (11):

To 2-(4-Chlorophenyl)-ethylamine (5g, 32.1 mmol) in CH_3CN (150 ml) was added Et_3N (5.4 ml, 38.5 mmol) at 0°C under a N_2 atmosphere followed by chloroacetyl chloride (2.83 ml, 35.34 mmol). The reaction mixture was stirred at 0°C for 0.5h and at room temperature for 3h. Then solvent was evaporated, the crude mixture was dissolved in EtOAc (100 ml) and poured into 200 ml of H_2O. The organic layer was separated, the water layer was extracted with EtOAc, the combined organic extract was washed with H_2O, brine, dried over $MgSO_4$, and the solvent was removed. The crude compound was dissolved in 30 ml of EtOAc, hexane (150ml) was added and cooled to 0°C to precipitate the brown solid. The solid was filtered and dried to afford 4.9g of **11** in 67% yield.

^{1}H NMR ($CDCl_3$, 400MHz): δ2.82 (t, 2H, J=6.8 Hz), 3.54 (q, 2H, J=6.4Hz), 4.02 (s, 2H), 6.55-6.65 (bs, 1H), 7.12-7.15 (m, 2H), 7.26-7.30 (m, 2H).

Preparation of 8-Chloro-1,3,4,5-tetrahydro-benzo[d]azepin-2-one (12) :

To the acetamide **11** (4.9g, 21.12 mmol) $AlCl_3$ (8.47g, 63.36 mmol) was added and the reaction mixture was heated at 150°C neat for 12h. Then the reaction mixture was cooled down to room temperature and quenched by the addition of 10% aq. HCl dropwise. EtOAc (100ml) was added to this and the layers were separated. The water layer was extracted with EtOAc (2x50ml) and the combined organic extract was washed with water, and brine, dried over $MgSO_4$, and solvent was removed. The crude compound was purified by flash column chromatography using 85% EtOAc in hexane as eluent to afford **12** (3.2g, 77.5 %) as an off white solid with less than 10 % other impurity.

^{1}H NMR ($CDCl_3$, 400MHz): δ3.06-3.13 (m, 2H), 3.53-3.58 (m, 2H), 3.79 (s, 2H), 6.37 (bs, 1H), 7.03-7.17 (m, 3H). LC/MS =196 (M+1).

Preparation of 7-Chloro-1,2,4,5-tetrahydro-benzo[d]azepine-3-carboxylic acid tert-butyl ester (13) :

To the amide **12** (0.75g, 3.84 mmol) in dry THF (50ml) was added BH_3.DMS (13.5 ml, 13.46 mmol, 2M in toluene) at 0°C under N_2 atmosphere and the reaction mixture was stirred at room temperature for 12h. Then the reaction mixture was quenched by the addition of 20 ml of 10% aq. HCl and refluxed for 1h. After the reaction mixture was brought to room temperature, the organic solvent was evaporated; the water layer was extracted with EtOAc (50ml) to remove any unreacted starting material or non polar impurities. The water layer was basified with the addition of 1N aq. NaOH solution and extracted with EtOAc (3x50ml). The combined organic extract was washed with water, and brine, dried over $MgSO_4$, and solvent was removed. The

crude oily compound (0.3g) was dissolved in MeOH (30ml) and Et_3N (0.58ml, 1.37 mmol) was added followed by $(Boc)_2O$ (0.6g, 2.75 mmol) The reaction mixture was stirred at room temperature for 12h. Solvents were evaporated and the crude mixture was purified by flash column chromatography using 10% EtOAc in hexane as an eluent to afford **13** (0.18g, 40%) as a colorless gummy oil.

^1H NMR ($CDCl_3$, 400MHz): δ1.48 (s, 9H), 2.85 (bs, 1.5H), 2.95 (bs, 0.5H), 3.25 (bs, 0.5H), 3.53-3.54 (m, 4H), 7.02-7.10 (m, 3H).

Preparation of 7-(3-Methoxy-benzyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (1) :

To 3-methoxy benzylzinc chloride (*J. Am. Chem. Soc.*, 2001, 123, 2719-2724) (1.92 ml, 0.96 mmol, 0.5M in THF) in a dry 20ml microwave reactor vial N-methyl pyrrolidone (2.5ml) was added and stirred for 15 minute at room temperature under N_2 atmosphere. Then to the reaction mixture Pd $[P(t\text{-}Bu)_3]_2$ (6.5mg, 0.012 mmol) was added followed by the addition of **13** (0.18g, 0.64 mmol) in 2ml of THF. The mixture was heated to 150°C in microwave reactor for 30min, cooled to room temperature, and acidified by the addition of 5ml of 10% aq. HCl. The compound was extracted with EtOAC (3x20ml). The combined EtOAc extract was dried over $MgSO_4$ and the volatiles were removed under reduced pressure. The crude oil was purified by flash column chromatography and subjected to deprotection by treating with 5eq of TFA in CH_2Cl_2 at room temperature for 4h. Solvent was removed and the crude residue was dissolved in MeOH. Solid $NaHCO_3$ was added and stirred for 0.5h to make the solution basic. The mixture was filtered, the solvent was removed and the crude residue was purified by combiflash column chromatography using 10% MeOH + 5 % Et_3N in EtOAc as eluent to afford the amine **14** (0.1g) as colorless oil. The oil was taken in 1 ml of MeOH and to it 1eq. of 1N of fumaric acid in MeOH was added. Ether (50ml) was added to precipitate the fumarate salt which was filtered and dried to afford **1** (50 mg) as off white powder. ^1H NMR (CD_3OD, 400MHz): δ3.09-3.13 (m, 4H), 3.26-3.28 (m, 4H), 3.76 (s, 3H), 3.91 (s, 2H), 6.70 (s, 2H), 6.74-6.79 (m, 3H),

7.08 (s, 2H), 7.14-7.18 (m, 2H). ^{13}C NMR (CD_3OD, 100MHz): δ 33.25, 33.66, 42.31, 47.55, 47.62, 55.58, 112.30, 115.80, 122.26, 128.96, 130.45, 130.76, 131.14, 137.96, 140.33, 142.19, 144.03, 161.32. LC/MS =268 (M+1). Anal. Calcd. For $C_{22}H_{25}NO_5$: C, 68.91; H, 6.57; N, 3.65. Found: C, 68.48; H, 6.60; N, 3.67.

Example 2

3-(2,3,4,5-Tetrahydro-1H-benzo[d]azepin-7-ylmethyl)-phenol (2)

Preparation of 3-(2,3,4,5-Tetrahydro-1H-benzo[d]azepin-7-ylmethyl)-phenol (2):

To compound **14** (0.12g, 0.44 mmol) in CH_2Cl_2 (10mL) at room temperature under N_2 atmosphere was added BBr_3 (0.064ml, 0.67 mmol) drop wise. The reaction mixture was stirred there for 2h, and the solvent was evaporated. The solids were dissolved in H_2O, neutralized by the addition of solid $NaHCO_3$, and extracted with EtOAc. The combined extract was dried over $MgSO_4$, the solvent was evaporated and the fumarate salt (**2**, 0.14g) was made as described for **1**. ^1H NMR (CD_3OD, 400MHz): δ2.99-3.07 (m, 4H), 3.14-3.17 (m, 4H), 3.73 (s, 2H), 6.46-6.49 (m, 2H), 6.49-6.50 (m, 1H), 6.63 (s, 2H), 6.92-6.95 (m, 3H), 7.0-7.06 (m, 1H), 7.06-7.09 (m, 1H). LC/MS =254 (M+1).

Example 3

7-(3,5-Dimethoxy-benzyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (3)

Preparation of 7-(3,5-Dimethoxy-benzyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (3):

Compound **3** was prepared from **13** using 3,5-dimethoxy benzyl zinc chloride following the same procedure as described for example**1**.

^{1}H NMR (CD_3OD, 400MHz): δ2.99-3.00 (m, 4H), 3.14-3.17 (m, 4H), 3.62 (s, 6H), 3.74 (s, 2H), 6.23-6.24 (m, 3H), 6.58 (s, 2H), 6.95-6.98 (m, 2H), 7.14-7.18 (m, 1H). ^{13}C NMR (CD_3OD, 100MHz): δ33.26, 33.66,42.49, 47.54, 47.61, 55.66, 98.78, 108.12, 128.95, 130.73, 131.12, 137.99, 140.33, 142.04, 144.73, 162.43. LC/MS =298 (M+1). Anal. Calcd. For $C_{22}H_{25}NO_5$: C, 66.81; H, 6.58; N, 3.39. Found: C, 66.09; H, 6.12; N, 3.12.

Example 4

8-(4-hydroxybenzyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-ol (4)

8-(4-hydroxybenzyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-ol was prepared by the multiple step procedure outlined below.

Preparation of (4-methoxyphenyl)[8-methoxy-3-(trifluoroacetyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]methanone (16):

To compound **15** (*DE 3418270, 1985)* (0.38g, 1.30mmol) in CH_2Cl_2 (20mL) at room temperature under N_2 atmosphere was added $AlCl_3$ (0.55g, 4.15 mmol) followed by the addition of 4-methoxy benzoyl chloride (0.48 mL, 3.47 mmol). The reaction mixture was stirred at room temperature overnight, quenched with the addition of water (10mL), and extracted with EtOAc (3x50ml). The combined organic extract was washed with water, and brine, dried over $MgSO_4$ and evaporated to a crude residue. The crude mixture was purified by column chromatography using 30% EtOAc in hexane as eluent to afford the title compound **16** as an oil (0.35g, 61.7%).

^{1}H NMR ($CDCl_3$, 400MHz): δ2.94-2.96 (m, 2H), 3.00-3.02 (m, 2H), 3.68-3.88 (m, 4H), 3.72 (s, 3H), 3.87 (s, 3H), 6.76 (d, 1H, J = 12Hz), 6.90-6.95 (m, 2H), 7.12 (d, 1H, J = 8.4Hz), 7.78-7.80 (m, 2H). LC/MS = 408 (M+1).

Preparation of 7-methoxy-8-(4-methoxybenzyl)-3-(trifluoroacetyl)-2,3,4,5-tetrahydro-1H-3-benzazepine (17):

To the ketone **16** (0.35g, 0.85 mmol) in trifluroacetic acid (10mL) was added Et_3SiH (0.69 mL, 4.29 mmol) and the reaction mixture was stirred at room temperature for 12h. The solvent was evaporated and the crude mixture was purified by combiflash chromatography to afford 0.26g of **17** as light yellow oil.

^1H NMR ($CDCl_3$, 400MHz): δ2.82-2.84 (m, 2H), 2.90-2.94 (m, 2H), 3.61-3.72 (m, 4H), 3.77 (s, 3H), 3.81 (s, 3H), 3.85 (s, 2H), 6.64 (d, 1H, J = 12.8Hz), 6.78-6.82 (m, 3H), 7.10-7.13 (m, 2H). LC/MS = 411 (M+18).

Preparation of 8-(4-hydroxybenzyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-ol (4):

To compound **17** (0.1g, 0.25 mmol) in methanol:water (4:1,10 mL) was added 5 ml of 5N aq. NaOH solution and the reaction mixture was stirred at room temperature for 12h. Then methanol was removed and compound was extracted with EtOAc (3x15mL). The combined extract was washed with water, brine, dried over $MgSO_4$ and evaporated to afford the crude amine. The crude amine was dissolved in 15 mL of CH_2Cl_2, BBr_3 (0.085 mL, 0.9 mmol) was added and the resulting solution was stirred at room temperature for 2h. The reaction mixture was quenched with 2 mL of methanol, and the volatiles were removed. The crude solid was dissolved in 1ml of methanol and ether (20mL) was added to precipitate the HBr salt. Solids were filtered, washed with ether and dried in vacuum to afford **5** (34mg) as off white powder.

^1H NMR (CD_3OD, 400MHz): δ2.99-3.06 (m, 4H), 3.18-3.25 (m, 4H), 3.82 (s, 2H), 6.63 (s, 1H), 6.72-6.79 (m, 3H), 7.04-7.06 (m, 2H), 7.45 (s, 1H). ^{13}C NMR (CD_3OD, 100MHz): δ 32.22, 32.67, 34.69, 47.03, 47.37, 115.61, 116.83, 127.94, 129.73, 130.36, 132.09, 132.44, 137.70, 154.36, 155.39.

LC/MS =270 (M+1). Anal. Calcd. For $C_{17}H_{20}NO_2$, 0.33 mol of H_2O: C, 57.31; H, 5.85; N, 3.93. Found: C, 57.23; H, 5.84; N, 3.79.

Example 5

8-(3-hydroxybenzyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-ol (5)

Preparation of 8-(3-hydroxybenzyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-ol (5)

Compound **5** was made from **15** following the same procedures described for **4** using 3-methoxy benzoyl chloride as the acylating reagent.

^{1}H NMR (CD_3OD, 400MHz): δ2.99-3.06 (m, 4H), 3.21-3.23 (m, 4H), 3.72 (s, 2H), 6.55-6.57 (m, 1H), 6.59-6.63 (m, 3H), 6.76 (s, 1H), 6.93-6.95 (m, 1H). ^{13}C NMR (CD_3OD, 100MHz): δ 32.81, 33.37, 35.97, 47.73, 48.07, 113.66, 116.80, 117.31, 121.23, 127.98, 130.13, 130.76, 132.91, 138.94, 144.18, 155.31, 158.33. LC/MS =270 (M+1). Anal. Calcd. For $C_{17}H_{20}NO_2$, 0.33 mol of H_2O: C, 57.31; H, 5.85; N, 3.93. Found: C, 57.16; H, 5.81; N, 3.74.

Example 6

3-(trifluoroacetyl)-2,3,4,5-tetrahydro-1H-3-benzazepine (18)

The preparation of 3-(trifluoroacetyl)-2,3,4,5-tetrahydro-1H-3-benzazepine (18) was by the multiple step process described below.

Compound **18** was prepared from phenyl ethylamine following the same procedure as described for **15**.

^{1}H NMR ($CDCl_3$, 400MHz): δ2.96-3.0 (m, 4H), 3.68-3.70 (m, 2H), 3.76-3.79 (m, 2H), 7.12-7.19 (m, 4H).

Preparation of 7-(chloromethyl)-3-(trifluoroacetyl)-2,3,4,5-tetrahydro-1H-3-benzazepine (19):

To the compound **18** (0.5g, 2.05 mmol) in CH_2Cl_2 (20 mL) at -10°C was added $SnCl_4$ (0.84 mL, 7.20 mmol) followed by $ClCH_2OCH_3$ (0.24 mL, 5.14 mmol). The reaction mixture was stirred at room temperature for 24h, quenched with water, and extracted with EtOAc (3x25ml). The combined extract was washed with water, and brine, dried over $MgSO_4$. The volatiles were evaporated to afford residue which was purified by flash column chromatography using 10% EtOAc in hexane as eluent to afford **19** (0.5g) as an oil.

^1H NMR ($CDCl_3$, 400MHz): δ2.95-3.02 (m, 4H), 3.69-3.70 (m, 2H), 3.75-3.79 (m, 2H), 4.55 (s, 2H), 7.12-7.22 (m, 3H).

Preparation of 7-[(3-methoxyphenoxy)methyl]-3-(trifluoroacetyl)-2,3,4,5-tetrahydro-1H-3-benzazepine (20):

To the compound **19** (0.2g, 0.68 mmol) in CH_3CN (20 mL) was added K_2CO_3 (0.28g, 2.06 mmol) followed by 3-methoxy phenol (0.09 mL, 0.82 mmol) and KI (0.12g, 0.75 mmol) and the reaction mixture was stirred at room temperature for 12h. Solids were filtered and solvents were evaporated to a crude mixture which was purified by flash column chromatography using 15% EtOAc in hexane as eluent to afford **20** (0.18g).

^1H NMR ($CDCl_3$, 400MHz): δ2.96-3.01 (m, 4H), 3.69-3.70 (m, 2H), 3.75-3.79 (m, 5H), 4.99 (s, 2H), 6.56-6.58 (m, 3H), 7.12-7.25 (m, 4H). LC/MS = 380 (M+1).

Preparation of 7-[(3-methoxyphenoxy)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepine (6):

To the compound 20 (0.18g, 0.47 mmol) in methanol:water (4:1,10 mL) was added 5 ml of 5N aq. NaOH solution and the reaction mixture was stirred at room temperature for 12h. Then methanol was removed and compound

was extracted with EtOAc (3x15ml). The combined extract was washed with water, and brine, dried over $MgSO_4$ and evaporated to yield the crude amine. The amine was purified by column chromatography using a mixture of 10% methanol, 5% Et_3N and 85% EtOAc as eluent to afford the amine **6**. The amine was converted to its fumarate salt (77 mg) as described for compound **1**.

^1H NMR (CD_3OD, 400MHz): δ3.16-3.19 (m, 4H), 3.30-3.32 (m, 4H), 3.77 (s, 3H), 5.05 (s, 2H), 6.51-6.54 (m, 3H), 6.70 (s, 2H), 7.14-7.18 (m, 1H), 7.24-7.26 (m, 1H), 7.30-7.33 (m, 2H). ^{13}C NMR (CD_3OD, 100MHz): δ33.37, 33.66, 47.50, 55.69, 70.45, 102.40, 107.45, 108.18, 127.70, 129.80, 130.82, 130.94, 137.50, 139.90, 141.12, 161.56, 163.32.. LC/MS =284 (M+1). Anal. Calcd. For $C_{22}H_{25}NO_6$, 0.12 mol of H_2O: C, 65.78; H, 6.34; N, 3.49. Found: C, 65.87; H, 6.31; N, 3.47.

Example 7

3-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-ylmethoxy)phenol (7):

3-(2,3,4,5-Tetrahydro-1H-3-benzazepin-7-ylmethoxy)phenol (7) was prepared by the multiple step process outlined below.

Preparation of 3-{[3-(trifluoroacetyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]methoxy}phenyl acetate (21):

Compound **21** was made from **19** following the same procedure described for **20** using resorcinol monoacetate as alkylating agent.

^1H NMR ($CDCl_3$, 400MHz): δ2.28 (s, 3H)2.96-3.01 (m, 4H), 3.69-3.70 (m, 2H), 3.77-3.78 (m, 2H), 4.99 (s, 2H), 6.72-6.73 (m, 2H), 6.83-6.85 (m, 1H), 7.19-7.23 (m, 4H). LC/MS = 408 (M+1).

Preparation of 3-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-ylmethoxy)phenol (7):

Compound **7** was prepared from **21** following the same procedure as described for compound **6**.

^{1}H NMR (CD_3OD, 400MHz): δ3.15-3.18 (m, 4H), 3.29-3.31 (m, 4H), 4.96 (s, 2H), 6.26-6.47 (m, 3H), 6.70 (s, 2H), 7.04-7.11 (m, 1H), 7.23-7.35 (m, 4H). LC/MS = 270 (M+1). Anal. Calcd. For $C_{21}H_{23}$ NO_6, 0.33 mol of H_2O: C, 64.44; H, 6.09; N, 3.58. Found: C, 64.06; H, 6.02; N, 3.76.

Example 8

7-[(3-methoxybenzyl)oxy]-8-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine (8):

7-[(3-Methoxybenzyl)oxy]-8-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine (8) was prepared by the multiple step process outlined below.

Preparation of (3-methoxy-4-methylphenyl)acetic acid (23):

To 3-methoxy-4-methylphenyl acetonitrile (3g, 18.63 mmol) in ethanol (100 mL) was added 20 mL of 10% aqueous NaOH solution. The reaction mixture was refluxed for 20 h. Ethanol was removed, the crude mixture was dissolved in water (100 mL) and adjusted to pH 4 by adding conc. HCl. Solids that formed were filtered, washed with water, and dried in vacuum to give **23** (2.64g) as off white solid.

^{1}H NMR ($CDCl_3$, 400MHz): δ2.18 (s, 3H), 3.60 (s, 2H), 3.81 (s, 3H), 6.73-6.77 (m, 2H), 7.07 (d, 1H, J = 7.6 Hz). LC/MS = 180 (M+1).

Preparation of 7-methoxy-8-methyl-3-(trifluoroacetyl)-2,3,4,5-tetrahydro-1H-3-benzazepine (24):

Compound **24** was prepared from **23** following the same procedures as compound **15**.

^{1}H NMR ($CDCl_3$, 400MHz): δ2.17 (s, 3H), 2.86-2.95 (m, 4H), 3.64-3.69 (m, 2H), 3.72-3.81 (m, 2H), 3.81 (s, 3H), 6.60 (d, 1H, J = 12 Hz), 6.90 (d, 1H, J = 13.2 Hz). LC/MS = 288 (M+1).

Preparation of 8-methyl-3-(trifluoroacetyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-ol (25):

To compound **24** (0.5g, 1.74 mmol) in CH_2Cl_2 (30 mL) at 0°C was added BBr_3 (0.25 mL, 2.61 mmol). The reaction mixture was stirred at room temperature for 3h, and quenched with 5 mL of methanol. The solvent was removed and the crude mixture was purified by chromatography to afford **25** (0.45g).

^{1}H NMR ($CDCl_3$, 400MHz): δ2.20 (s, 3H), 2.85-2.89 (m, 4H), 3.63-3.67 (m, 2H), 3.71-3.75 (m, 2H), 3.69-4.71 (m, 1H), 6.59 (d, 1H, J = 7.6 Hz), 6.88 (d, 1H, J = 12.4 Hz). LC/MS = 274 (M+1).

Preparation of 7-[(3-methoxybenzyl)oxy]-8-methyl-3-(trifluoroacetyl)-2,3,4,5-tetrahydro-1H-3-benzazepine (26):

Compound **26** was made from **25** using 3-methoxy benzyl bromide as alkylating agent following the same procedure as described for compound **20**.

^{1}H NMR ($CDCl_3$, 400MHz): δ2.24 (s, 3H), 2.86-2.92 (m, 4H), 3.64-3.67 (m, 2H), 3.72-3.76 (m, 2H), 3.82 (s, 3H), 5.02 (s, 2H), 6.94 (d, 1H, J = 12 Hz), 7.0-7.02 (m, 2H), 7.28-7.31 (m, 1H). LC/MS = 394 (M+1).

Preparation of 7-[(3-methoxybenzyl)oxy]-8-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine (8):

Compound **8** was prepared from **26** following the same procedure as described for compound **6**.

^{1}H NMR (CD_3OD, 400MHz): δ2.94-2.99 (m, 4H), 3.13-3.17 (m, 4H), 3.71 (s, 3H), 4.98 (s, 2H), 6.58 (s, 1.5H), 6.73 (s, 1H), 6.78-6.82 (m, 1H),

6.91-6.92 (m, 3H), 7.17-7.19 (m, 1H). ^{13}C NMR (CD_3OD, 100MHz): δ15.95, 32.81, 33.63, 47.63, 47.85, 55.67, 70.96, 113.81, 114.11, 114.31, 120.39, 126.68, 130.59, 132.15, 133.11, 138.72, 140.51, 157.17, 161.36. LC/MS =298 (M+1). Anal. Calcd. For $C_{19}H_{23}NO_2$, 0.85 mol of fumaric acid: C, 67.87; H, 6.71; N, 3.53. Found: C, 67.81; H, 6.74; N, 3.63.

The compounds of this invention can be incorporated into various types of ophthalmic formulations for delivery to the eye (e.g., topically, intracamerally, or via an implant). The compounds are preferably incorporated into topical ophthalmic formulations for delivery to the eye. The compounds may be combined with ophthalmologically acceptable preservatives, surfactants, viscosity enhancers, penetration enhancers, buffers, sodium chloride, and water to form an aqueous, sterile ophthalmic suspension or solution. Ophthalmic solution formulations may be prepared by dissolving a benzodifuran analog in a physiologically acceptable isotonic aqueous buffer. Further, the ophthalmic solution may include an ophthalmologically acceptable surfactant to assist in dissolving the benzodifuran analog. Furthermore, the ophthalmic solution may contain an agent to increase viscosity, such as, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylmethylcellulose, methylcellulose, polyvinylpyrrolidone, or the like, to improve the retention of the formulation in the conjunctival sac. Gelling agents can also be used, including, but not limited to, gellan and xanthan gum. In order to prepare sterile ophthalmic ointment formulations, the active ingredient is combined with a preservative in an appropriate vehicle, such as, mineral oil, liquid lanolin, or white petrolatum. Sterile ophthalmic gel formulations may be prepared by suspending the compound of Formula A in a hydrophilic base prepared from the combination of, for example, carbopol-974, or the like, according to the published formulations for analogous ophthalmic preparations; preservatives and tonicity agents can be incorporated.

The compounds of the present invention are preferably formulated as topical ophthalmic suspensions or solutions, with a pH of about 4 to 8. The compounds will normally be contained in these formulations in an amount 0.01 to 5% (w/v), but preferably in an amount of 0.1 to 2% (w/v). Thus, for topical presentation 1 to 2 drops of these formulations would be delivered to

the surface of the eye 1 to 4 times per day according to the discretion of a skilled clinician.

The compounds of Formula A can also be used in combination with other agents for treating glaucoma, such as, but not limited to, β-blockers (e.g., timolol, betaxolol, levobetaxolol, carteolol, levobunolol, propranolol), carbonic anhydrase inhibitors (e.g., brinzolamide and dorzolamide), α_1 antagonists (e.g. nipradolol), α_2 agonists (e.g., iopidine and brimonidine), miotics (e.g., pilocarpine and epinephrine), prostaglandin analogs (e.g., latanoprost, travoprost, unoprostone, and compounds set forth in U.S. Patent Nos. 5,889,052; 5,296,504; 5,422,368; and 5,151,444, "hypotensive lipids" (e.g., lumigan and compounds set forth in 5,352,708), and neuroprotectants (e.g., compounds from U.S. Patent No. 4,690,931, particularly eliprodil and R-eliprodil, as set forth in a pending application U.S.S.N. 06/203350, and appropriate compounds from WO94/13275, including memantine.

The following methods can be used to characterize the compounds of the present invention.

METHOD 1

r5-HT_{2A} Functional Assay: FLIPR

Rat Vascular Smooth Muscle Cells

The receptor-mediated mobilization of intracellular calcium ($[Ca^{2+}]_i$) was studied using the Fluorescence Imaging Plate Reader (FLIPR) instrument. Rat vascular smooth muscle cells, A7r5, were grown in a normal media of DMEM / 10% FBS and 10 μg/ml gentamycin. Confluent cell monolayers were trypsinized, pelleted, and re-suspended in normal media. Cells were seeded in a 50 μL volume at a density of 20,000 cells per well in a black wall, 96-well tissue culture plate and grown for 2 days. On the day of the experiment, one vial of FLIPR Calcium Assay Kit dye was re-suspended in 50 ml of a FLIPR buffer consisting of Hank's Balanced Salt Solution (HBSS), 20 mM HEPES, and 2.5 mM probenecid, pH 7.4. Cells were loaded with the calcium-sensitive dye by addition of an equal volume (50 μl) to each well of the 96-well plate and incubated with dye for 1 h at 23°C. Typically, test compounds were stored at 25 μM in 50% DMSO/50% Ethanol solvent. Compounds were diluted 1:50 in 20% DMSO/20% Ethanol. For dose-response experiments,

compounds were diluted 1:50 in FLIPR buffer and serially diluted 1:10 to give a 5- or 8- point dose-response curve.

At the beginning of an experimental run, a signal test was performed to check the basal fluorescence signal from the dye-loaded cells and the uniformity of the signal across the plate. The basal fluorescence was adjusted between 8000-12000 counts by modifying the exposure time, the camera F-stop, or the laser power. The instrument settings for a typical assay were as follows: laser power 0.3-0.6 W, camera F-stop F/2, and exposure time 0.4 sec. An aliquot (25 µl) of the test compound was added to the existing 100 µl dye-loaded cells at a dispensing speed of 50 µl/sec. Fluorescence data were collected in real-time at 1.0 sec intervals for the first 60 sec and at 6.0 sec intervals for an additional 120 sec. Responses were measured as peak fluorescence intensity minus basal and where appropriate were expressed as a percentage of a maximum 5-HT-induced response.

METHOD 2

r5-HT_{2C} Functional Assay: FLIPR

This assay were performed as for the r5-HT_{2A} receptor above, except that SR3T3 cells expressing the recombinant rat 5-HT_{2C} receptor were utilized.

METHOD 2

h5-HT_2 Functional Assay

Functional response at the 5-HT_2 receptor subtypes was determined using CHO-K1 cells stably expressing mitochondrially-targeted bioluminescent aequorin, $G_{\alpha 16}$, and one of either human serotonin receptor clone 5-HT_{2A}, 5-HT_{2B}, or 5-HT_{2C}. Prior to testing, cells were loaded in suspension with coelenterazine for 4-16 hours and directly injected onto different concentrations of the test compound. Light emitted from the cells was measured 20-30 seconds following receptor activation. A luminometer (Hamamatsu, FDSS-6000) was used to record luminescence in response to the test compound. The mean response signal at each of 8-11 different concentrations was integrated to provide an estimation of receptor activation,

expressed as the EC_{50} value. The efficacy of the response (E_{max}) at the 5-HT_{2A} and 5-HT_{2B} receptors is expressed relative to the response of α-methyl-5-HT under the same assay conditions while the efficacy at 5-HT_{2C} is expressed relative to the response of 5-HT.

The above procedures were used to generate the data shown in Table 1.

Table 1. 5-HT2 Functional Data.

Example	Structure	r5-HT		h5-HT		
		2A EC_{50} nm (E_{max})	2C EC_{50} nm (E_{max})	2A EC_{50} nm (E_{max})	2B EC_{50} nm (E_{max})	2C EC_{50} nm (E_{max})
1		386 (39)	82 (100)	1.5 (102)	390 (87)	1.1 (105)
2		>1000	120 (100)	31 (98)	1242 (35)	8.8 (109)
3		>10,000	629 (70)	16.9 (104)	>10000 (6)	20 (105)
4		1.13 (45%)	1.48 (81)	1.2 (106)	43 (73)	0.3 (110)
5		8.9 (45)	0.8 (108)	1.2 (106)	8.4 (84)	0.22 (108)
6		69 (35%)	91 (89%)	0.4 (105)	417 (61)	3.9 (107)
7		440 (40%)	65 (92)	----------	----------	----------
8		1920 (48%)	250 (102)	2.4 (102)	230 (63)	4.5 (101)

METHOD 3

Acute IOP Response in Lasered (Hypertensive) Eyes of Conscious Cynomolgus Monkeys

Intraocular pressure (IOP) can be determined with an Alcon Pneumatonometer after light corneal anesthesia with 0.1% proparacaine. Eyes are washed with saline after each measurement. After a baseline IOP measurement, test compound is instilled in one 30 µL aliquot to the right eyes only of nine cynomolgus monkeys. Vehicle is instilled in the right eyes of six additional animals. Subsequent IOP measurements are taken at 1, 3, and 6 hours.

The above method was used to determine the IOP lowering efficacy of Compound 1. All eyes were pretreated with 1 drop of 0.5% proparacaine to address discomfort. The results are shown in Table 2.

Table 2. IOP Efficacy.

Compound	Dose (µg)	Baseline IOP (mmHg)	% IOP change (mmHg)		
			1 hr	3hr	6 hr
1	100	38.3	-16.5 (6.6)	-33.1 (13.1)	-42.5 (16.8)
1	150	40.4	-15.6 (6.1)	-29.5 (12.3)	-37.8 (15.6)

The following topical ophthalmic formulations are useful according to the present invention administered 1-4 times per day according to the discretion of a skilled clinician.

EXAMPLE 9

Ingredients	Amount (wt %)
Compound 1	0.1 – 2
Hydroxypropyl methylcellulose	0.5
Dibasic sodium phosphate (anhydrous)	0.2
Sodium chloride	0.5
Disodium EDTA (Edetate disodium)	0.01
Polysorbate 80	0.05
Benzalkonium chloride	0.01
Sodium hydroxide / Hydrochloric acid	For adjusting pH to 6.8 – 7.4
Purified water	q.s. to 100

EXAMPLE 10

Ingredients	Amount (wt %)
Compound 1	0.1 – 2
Methyl cellulose	4.0
Dibasic sodium phosphate (anhydrous)	0.2
Sodium chloride	0.5
Disodium EDTA (Edetate disodium)	0.01
Polysorbate 80	0.05
Benzalkonium chloride	0.01
Sodium hydroxide / Hydrochloric acid	For adjusting pH to 6.8 – 7.4
Purified water	q.s. to 100

EXAMPLE 11

Ingredients	Amount (wt %)
Compound 1	0.1 – 2
Guar gum	0.4- 6.0
Dibasic sodium phosphate (anhydrous)	0.2
Sodium chloride	0.5
Disodium EDTA (Edetate disodium)	0.01
Polysorbate 80	0.05
Benzalkonium chloride	0.01
Sodium hydroxide / Hydrochloric acid	For adjusting pH to 6.8 – 7.4
Purified water	q.s. to 100

5

EXAMPLE 12

Ingredients	Amount (wt %)
Compound 1	0.1 – 2
White petrolatum and mineral oil and lanolin	Ointment consistency
Dibasic sodium phosphate (anhydrous)	0.2
Sodium chloride	0.5
Disodium EDTA (Edetate disodium)	0.01
Polysorbate 80	0.05
Benzalkonium chloride	0.01
Sodium hydroxide / Hydrochloric acid	For adjusting pH to 6.8 – 7.4

We Claim:

1. A method for lowering or controlling intraocular pressure in a warm-blooded mammal's eye, which comprises administering to the mammal a composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a compound of formula **A**:



Formula **A**

wherein:

R^1 = H or C_{1-4} alkyl;

R^2 = H, OH, or OR where R = C_{1-4} alkyl;

R^3 = -X-Ar, $-OR^8$, $-(CH_2)_nOR^8$, or $-(CH_2)_{n'}-O-(CH_2)_mOR^8$;

R^4, R^5 = H or C_{1-2} alkyl;

R^6, R^7 = H or C_{1-2} alkyl;

when R^4 or R^5 = C_{1-2} alkyl , then R^6 = R^7 = H;

when R^6 or R^7 = C_{1-2} alkyl, then R^4 = R^5 = H;

R^8, R^9, R^{10} = H or C_{1-4} alkyl;

n = 1-4;

n' = 1-4;

m = 1-4;

X = O, $-C(R^9)(R^{10})-$, $-OC(R^9)(R^{10})-$, or $-C(R^9)(R^{10})O-$;

Ar = phenyl, optionally mono- or di-substituted with F, Cl, Br, I, C_{1-4} alkyl, OH, or OR^8; or 2-, 3-, 4- pyridyl, optionally mono- or di-substituted with F, Cl, Br, I, C_{1-4} alkyl, OH, or OR^8;

and pharmaceutically acceptable salts thereof.

2. The method of Claim 1 wherein for the compound of formula **A**

R_1 = H;

R_2 = OH, or OR, where R = C_{1-4} alkyl;

R^4, R^5 = H or C_1 alkyl;

R^6, R^7 = H or C_1 alkyl;

when R^4 or R^5 = C_1 alkyl, then R^6 = R^7 = H;

when R^6 or R^7 = C_1 alkyl, then R^4 = R^5 = H;

R^8 = C_{1-4} alkyl; and

Ar = phenyl, optionally mono- or di-substituted with F, Cl, Br, C_{1-2} alkyl, OH, or OR^8.

3. The method of Claim 1 wherein the compound is selected from the group consisting of: 7-(3-Methoxy-benzyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine fumarate; 8-(4-Hydroxy-benzyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ol hydrobromide; and pharmaceutically acceptable salts thereof.

4. The method of Claim 1 wherein the mammal is a human, the composition is a topically administered ophthalmic composition, and the pharmaceutically effective amount of the compound is 0.01 – 5 % (w/v).

5. The method of Claim 4 wherein the pharmaceutically effective amount of the compound is 0.1 - 2 % (w/v).

6. A method for treating glaucoma in a mammal, which comprises administering to the mammal a composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a compound of formula **A**:



Formula **A**

wherein

R^1 = H or C_{1-4} alkyl;

R^2 = H, OH, or OR where R = C_{1-4} alkyl;

R^3 = -X-Ar, $-OR^8$, $-(CH_2)_nOR^8$, or $-(CH_2)_{n'}-O-(CH_2)_mOR^8$;

R^4, R^5 = H or C_{1-2} alkyl;

R^6, R^7 = H or C_{1-2} alkyl;

when R^4 or R^5 = C_{1-2} alkyl , then R^6 = R^7 = H;

when R^6 or R^7 = C_{1-2} alkyl, then R^4 = R^5 = H;

R^8, R^9, R^{10} = H or C_{1-4} alkyl;

n = 1-4;

n' = 1-4;

m = 1-4;

X = O, -$C(R^9)(R^{10})$-, -$OC(R^9)(R^{10})$-, or -$C(R^9)(R^{10})O$-;

Ar = phenyl, optionally mono- or di-substituted with F, Cl, Br, I, C_{1-4} alkyl, OH, or OR^8; or 2-, 3-, 4- pyridyl, optionally mono- or di-substituted with F, Cl, Br, I, C_{1-4} alkyl, OH, or OR^8;

and pharmaceutically acceptable salts thereof.

7. The method of Claim 6 wherein for the compound of formula **A**
R_1 = H;

R_2 = OH, or OR, where R = C_{1-4} alkyl;

R^4, R^5 = H or C_1 alkyl;

R^6, R^7 = H or C_1 alkyl;

when R^4 or R^5 = C_1 alkyl, then R^6 = R^7 = H;

when R^6 or R^7 = C_1 alkyl, then R^4 = R^5 = H;

R^8 = C_{1-4} alkyl; and

Ar = phenyl, optionally mono- or di-substituted with F, Cl, Br, C_{1-2} alkyl, OH, or OR^8.

8. The method of Claim 6 wherein the compound is selected from the group consisting of: 7-(3-Methoxy-benzyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine fumarate; 8-(4-Hydroxy-benzyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ol hydrobromide; and pharmaceutically acceptable salts thereof.

9. The method of Claim 6 wherein the mammal is a human, the composition is a topically administered ophthalmic composition, and the pharmaceutically effective amount of the compound is 0.01 – 5 % (w/v).

10. The method of Claim 9 wherein the pharmaceutically effective amount of the compound is 0.1 - 2 % (w/v).

11. A compound of the formula:



wherein

R^1 = H;

R^2 = H, OH, or OR where R = C_{1-4} alkyl;

R^3 = -X-Ar, $-OR^8$, $-(CH_2)_nOR^8$, or $-(CH_2)_{n'}-O-(CH_2)_mOR^8$;

R^4, R^5 = H;

R^6, R^7 = H;

R^8 = C_{1-4} alkyl;

R^9, R^{10} = H or C_{1-4} alkyl;

n = 1-4;

n' = 1-4;

m = 2-4;

X = O, $-C(R^9)(R^{10})-$, $-OC(R^9)(R^{10})-$, or-$C(R^9)(R^{10})O-$;

Ar = phenyl, optionally mono- or di-substituted with F, Cl, Br, C_{1-2} alkyl, OH, or OR^8; or 2-, 3-, 4- pyridyl, optionally mono- or di-substituted with F, Cl, Br, I, C_{1-4} alkyl, OH, or OR^8;

and pharmaceutically acceptable salts thereof.

12. The compound of Claim 11 wherein R = C_1 alkyl.

13. The compound of Claim 11 selected from the group consisting of: 7-(3-Methoxy-benzyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine fumarate; 8-(4-Hydroxy-benzyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ol hydrobromide; and pharmaceutically acceptable salts thereof.